Saltar ao contenido
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Idioma
Todos os campos
Title
Autor
Subject
Número de Clasificación
ISBN/ISSN
Tag
Buscar
Avanzado
Biochemical safety and efficac...
Citar
Text this
Enviar este rexistro por email
Imprimir
Exportar rexistro
Exportar a RefWorks
Exportar a EndNoteWeb
Exportar a EndNote
Permanent link
Biochemical safety and efficacy of co-administration of Ezetimibe and simvastatin among patients with chronic kidney disease: The second UK-Heart and renal protection (UK-HARP-II) study
Detalles Bibliográficos
Main Authors:
Landray, M
,
Baigent, C
,
Leaper, C
Formato:
Conference item
Publicado:
2003
Existencias
Descripción
Títulos similares
Staff View
Descripción
Summary:
Títulos similares
The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.
por: Landray, M, et al.
Publicado: (2006)
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease.
por: Baigent, C, et al.
Publicado: (2005)
Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: Final results of the first UK-Heart and Renal Protection (UK-HARP-1) study.
por: Baigent, C, et al.
Publicado: (2002)
Ezetimibe/simvastatin (vytorin) in heart and renal protection: The SHARP trial
por: Alexander, W, et al.
Publicado: (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
por: Baigent, C, et al.
Publicado: (2011)